Your browser doesn't support javascript.
A SARS-CoV-2 Infection High-Uptake Program on Healthcare Workers and Cancer Patients of the National Cancer Institute of Naples, Italy.
Crispo, Anna; Di Gennaro, Piergiacomo; Coluccia, Sergio; Gandini, Sara; Montagnese, Concetta; Porciello, Giuseppe; Nocerino, Flavia; Grimaldi, Maria; Tafuri, Mariangela; Luongo, Assunta; Rotondo, Emanuela; Amore, Alfonso; Labonia, Francesco; Meola, Serena; Marone, Stefanie; Pierro, Giovanni; Menegozzo, Simona; Miscio, Leonardo; Perri, Francesco; Rainisio, Maurizio; Bianchi, Attilio A M; Cavalcanti, Ernesta; Cascella, Marco; Celentano, Egidio.
  • Crispo A; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Di Gennaro P; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Coluccia S; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Gandini S; Department of Experimental Oncology, European Institute of Oncology (IEO)-IRCCS, 20141 Milan, Italy.
  • Montagnese C; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Porciello G; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Nocerino F; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Grimaldi M; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Tafuri M; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Luongo A; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Rotondo E; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Amore A; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Labonia F; Laboratory Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Meola S; Laboratory Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Marone S; Laboratory Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Pierro G; Laboratory Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Menegozzo S; Medical Direction, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Miscio L; Medical Direction, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Perri F; Head and Neck Medical and Experimental Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Rainisio M; AbaNovus srl, 18038 Sanremo, Italy.
  • Bianchi AAM; Directorate-General for Management, IRCCS Fondazione G. Pascale, 80131 Naples, Italy.
  • Cavalcanti E; Laboratory Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
  • Cascella M; Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, 80131 Naples, Italy.
  • Celentano E; Epidemiology and Biostatistics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy.
Healthcare (Basel) ; 10(2)2022 Jan 20.
Article in English | MEDLINE | ID: covidwho-1650679
ABSTRACT

BACKGROUND:

From the beginning of 2020, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) quickly spread worldwide, becoming the main problem for the healthcare systems. Healthcare workers (HCWs) are at higher risk of infection and can be a dangerous vehicle for the spread of the virus. Furthermore, cancer patients (CPs) are a vulnerable population, with an increased risk of developing severe and lethal forms of Coronavirus Disease 19 (COVID-19). Therefore, at the National Cancer Institute of Naples, where only cancer patients are treated, a surveillance program aimed to prevent the hospital access of SARS-CoV-2 positive subjects (HCWs and CPs) was implemented. The study aims to describe the results of the monitoring activity for the SARS-CoV-2 spread among HCWs and CPs, from March 2020 to March 2021.

METHODS:

This surveillance program included a periodic sampling through nasopharyngeal molecular swabs for SARS-CoV-2 (Real-Time Polymerase Chain Reaction, RT-PCR). CPs were submitted to the molecular test at least 48 h before hospital admission. Survival analysis and multiple logistic regression models were performed among HCWs and CPs to assess the main SARS-CoV-2 risk factors.

RESULTS:

The percentages of HCWs tested with RT-PCR for the detection of SARS-CoV-2, according to the first and the second wave, were 79.7% and 91.7%, respectively, while the percentages for the CPs were 24.6% and 39.6%. SARS-CoV-2 was detected in 20 (1.7%) HCWs of the 1204 subjects tested during the first wave, and in 127 (9.2%) of 1385 subjects tested in the second wave (p < 0.001); among CPs, the prevalence of patients tested varied from 100 (4.6%) during the first wave to 168 (4.9%) during the second wave (p = 0.8). The multivariate logistic analysis provided a significant OR for nurses (OR = 2.24, 95% CI 1.23-4.08, p < 0.001) compared to research, administrative staff, and other job titles.

CONCLUSIONS:

Our findings show that the positivity rate between the two waves in the HCWs increased over time but not in the CPs; therefore, the importance of adopting stringent measures to contain the shock wave of SARS-CoV-2 infection in the hospital setting was essential. Among HCWs, nurses are more exposed to contagion and patients who needed continuity in oncological care for diseases other than COVID-19, such as suspected cancer.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Healthcare10020205

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Healthcare10020205